Definium Therapeutics Inc (DFTX) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
1 Feb, 2026Opening remarks and agenda
Meeting called to order with rules of conduct outlined for orderly proceedings and shareholder participation.
Cautionary note issued regarding forward-looking statements and associated risks.
Executive officers and meeting officials introduced, including CEO, Chief Legal Officer, and scrutineer.
Quorum confirmed and meeting declared duly constituted for business.
Corporate governance
Voting procedures explained, with electronic ballots and proxy instructions detailed.
Only board-nominated directors eligible for election, with six nominees listed.
All nominees currently serve as directors and have consented to act.
KPMG LLP nominated as independent auditor for the next term.
Board and executive committee updates
No new director nominations received; board composition remains unchanged.
Latest events from Definium Therapeutics Inc
- Pivotal phase III data for DT-120 in GAD and MDD expected this year, targeting broad market impact.DFTX
Stifel 2026 Virtual CNS Forum17 Mar 2026 - Phase III data for DT120 in GAD and MDD expected in 2024, targeting major unmet needs.DFTX
Leerink Global Healthcare Conference 202611 Mar 2026 - DT120 shows rapid, durable efficacy in GAD and MDD, with major Phase 3 readouts due in 2026.DFTX
TD Cowen 46th Annual Health Care Conference6 Mar 2026 - DT120 ODT advances in late-stage trials for GAD and MDD, targeting billion-dollar opportunities.DFTX
Corporate presentation27 Feb 2026 - Four phase III studies advance, with $411.6 million cash and key data readouts in 2026.DFTX
Q4 202526 Feb 2026 - MM120's phase III trials show rapid, durable efficacy, signaling a shift in psychiatric care.DFTX
Jefferies Global Healthcare Conference 20253 Feb 2026 - MM120 demonstrated rapid, durable efficacy in GAD, with phase III trials planned for year-end.DFTX
H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference3 Feb 2026 - Phase III trials for MM120 in GAD and MDD aim for durable, episodic treatment and broad impact.DFTX
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Q2 net loss narrowed to $5.9M; cash and new funding support MM120 phase III trials into 2027.DFTX
Q2 20241 Feb 2026